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Abstract: The prevalence of hypovitaminosis D has risen in developed countries over the past
few years in association with lifestyle changes and an increase in unhealthy habits. Vitamin D
deficiency has been implicated in various diseases, including metabolic syndrome (MetS), which is
clinically defined by a set of metabolic and vascular disorders. The objective of this study was to
review scientific evidence on the relationship between MetS and vitamin D deficiency to support
the development of prevention strategies and health education programs. An inverse relationship
has been reported between plasma vitamin D concentrations and the features that define MetS, i.e.,
elevated serum concentrations of glucose, total cholesterol, low-density lipoproteins, triglycerides,
glycosylated hemoglobin, and a high body mass index. Numerous studies have described the
benefits of vitamin D supplementation to improve outcomes in individuals with MetS. Interventions
to maintain optimal vitamin D concentrations are proposed as a preventive strategy against MetS.
Keywords: metabolic syndrome; vitamin D; cardiovascular risk; diabetes mellitus; obesity; insulin re-
sistance
1. Introduction
Metabolic syndrome (MetS) is characterized by the combination of central (intraab-
dominal) obesity, hypertension (HT), hyperglycemia, elevated serum levels of triglycerides
and cholesterol, reduced levels of high-density lipoproteins (HDLs), and insulin resistance
(IR). However, the definition and treatment of this syndrome remain controversial [1–3].
MetS is associated with a higher risk of developing cardiovascular disease and type 2
diabetes mellitus, and one of the variables most widely cited by clinicians to explain the
etiopathology of this syndrome is IR.
The prevalence of MetS has increased over the past few years, which has been at-
tributed not only to the aging of populations but also to the increase in obesity rates
associated with lifestyle changes, including less healthy eating habits and lower physical
activity levels. MetS is now considered a pandemic in developed countries and a source of
major public health concern [4–7].
Researchers have proposed that reduced serum vitamin D levels are related to an
increased risk of MetS [8]. The objective of the present study was to examine available
scientific evidence on the relationship of vitamin D deficiency with the onset and develop-
ment of MetS. These data will support the development of effective public health strategies
to prevent MetS and promote a healthy lifestyle.
2. Metabolic Syndrome
MetS is a set of metabolic conditions that increases the risk of cardiovascular disease
and diabetes. The components of MetS have been defined in various guidelines and
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consensus agreements [1–3] and currently comprise central (intraabdominal) obesity, HT,
IR, and dyslipidemia [9].
The prevalence of MetS is estimated to be 25% worldwide [10], varying widely as
a function of sex, age, and ethnicity [11,12]. A marked increase has been observed over
recent years in its prevalence among young adults. Due to this situation, the control of HDL
levels has been proposed as a preventive measure against MetS to reduce the incidence of
associated diseases [6].
The etiologies for MetS are overweight/obesity, lack of physical activity, and genetic
predisposition. The accumulation and dysfunction of adipose tissue result in IR, which
plays a decisive role in MetS development. The distribution of adipose tissue is also
considered an important factor, and the abdominal localization of excess adipose tissue has
been most closely associated with IR. The consequent microvascular damage can give rise
to vessel wall inflammation and HT, components of MetS [13].
3. Vitamin D
Vitamin D is a fat-soluble prohormone that plays an essential role in bone mineral
metabolism, being involved in calcium and phosphorus metabolism and skeletal home-
ostasis. The main source of vitamin D is cholecalciferol or vitamin D3, synthesized by
sunlight on the skin from 7-dehydrocholesterol, for which cholesterol is a precursor [14].
It is also available in the diet from animal (cholecalciferol) and vegetable (ergocalciferol)
foods. Regardless of the source, vitamin D requires two hydroxylations in the organism to
become biologically active, the first in the liver and the second in the kidney, resulting in
the form known as 1,25(OH)2 vitamin D or calcitriol (Figure 1) [15].
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Figure 1. Vitamin D synthesis pathways.
In the past, vitamin D was almost exclusively associated with bone health; however,
numerous other functions have gradually emerged, and deficiency of this vitamin has
been associated with a higher risk of certain autoimmune diseases [16]. These extraskeletal
actions are enabled by the presence of vitamin D receptors and hydroxylation enzymes in
the cells of different human tissues and by differences in vitami D production depending
on the tissue in which it is expressed. Therefore, the fact that the vitamin D receptor and the
enzyme 1α-hydroxylase are expressed in different tissues (kidney, pancreas, prostate, or
immune system) shows the possible action of this vitamin on these tissues. Thus, changes
in the expression of vitamin D receptors may be associated with the development of MetS
and its different components [17–19]. Vitamin D has also been attributed to hormonal
activity, including endocrine, autocrine, and paracrine functions [8]. In addition to all these
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activities, vitamin D has other functions of pleiotropic nature such as its anti-inflammatory,
anti-apoptotic and anti-fibrotic effects, preventive action against cardiovascular and renal
diseases, diabetes mellitus, or cancer through different mechanisms of action widely
described [20].
Interest in this vitamin has intensified over recent years due to the high prevalence
of hypovitaminosis D, described as a worldwide epidemic [21]. Based on the levels of
vitamin D, we can talk about insufficiency when 25(OH)D of 21–29 ng/mL, mild deficiency
when levels are between 10 and 20 ng/mL, moderate deficiency between 9 and 5 ng/mL,
and severe deficiency when vitamin D levels are lower than 5 ng/mL [22–24]. The very high
percentage of individuals with hypovitaminosis D has highlighted the need to implement
preventive strategies [25].
4. MetS and Vitamin D Deficiency
Numerous authors have addressed the possible association between micronutrient
deficiency and metabolic disorders, including MetS [25]. Various pathophysiologic mecha-
nisms have been proposed to underlie the effect of vitamin D on MetS components. One
plausible explanation is that vitamin D affects insulin secretion and sensitivity, which play
a key role in MetS development. The vitamin D receptor is expressed by β cells in the
pancreas and in musculoskeletal and adipose tissues, among other peripheral tissues, and
vitamin D deficiency can compromise the capacity of β cells to convert pro-insulin into
insulin [26]. Another pathophysiological mechanism could be related to the association
between obesity and vitamin D deficiency. The two most accepted hypotheses are vitamin
D sequestration and volumetric dilution. In the first case, this vitamin is sequestered in
adipose tissue, increased in obese individuals, which also influences a greater volumetric
dilution, according to which 25(OH)D, a fat-soluble molecule, would be distributed among
fat, muscle, liver, and serum, decreasing serum vitamin D levels. Other possible explana-
tions for this relationship described may be poor dietary habits, decreased sun exposure,
the difference in gene expression in vitamin D metabolizing enzymes, and impaired hepatic
25-hydroxylation [27,28].
Serum concentrations of vitamin D vary widely among different geographic areas,
largely attributable to differences in sun exposure, a key source of vitamin D [15]. Thus, the
frequency of hypovitaminosis, and therefore the potential risk of developing diabetes or
MetS is higher in populations living further from the equator, and differences in clothing
habits, skin color, and the use of sunscreen also play a role [29]. With regard to specific
populations, vitamin D deficiency in postmenopausal women seems to be associated
with a higher risk of MetS, hypertriglyceridemia, and lower HDL levels [26]. As noted
above, deficiency of this vitamin is more frequent in older age groups, with Navarro et al.
reporting that levels were inadequate in 50% of individuals aged 18 to 60 years and in 87%
in those aged over 65 years [30]. In this context, Xu et al. observed that those subjects with
genetically increased 25(OH)D concentration were less at risk of type 2 diabetes [31].
A study of non-diabetic young people also showed an inverse relationship between
vitamin D levels and the presence of MetS, attributed to the combined effect of obesity
and IR [32]. Lee et al. described a higher risk of MetS in Korean men and women aged
over 65 years with low 25(OH)D levels. After adjusting for age, area of residence, season,
and habits (exercise, tobacco, and alcohol), there appeared a relationship between low
vitamin D levels and increased prevalence of MetS, so the lower the vitamin D levels
(14.20–18.99 ng/mL in men and 11.20–15.59 ng/mL in women) the higher the prevalence
of elevated waist circumference, hypertriglyceridemia, and high low-density lipoprotein
cholesterol (LDL) concentrations [33]. Likewise, Zhu and Heil reported that 25(OH)D
levels were inadequate in 50% of the study population, formed by residents of Shanghai,
China, aged 19–70 years and were associated with the presence of MetS, observing a linear
relationship between 25(OH)D concentrations and serum concentrations of glucose and
lipids [34]. They calculated that each increase of 1 ng/mL 25(OH)D was associated with a
significant reduction in total cholesterol and LDL and a 54% decrease in the risk of MetS.
Nutrients 2021, 13, 830 4 of 17
Subsequent studies also reinforce the possible association between vitamin D deficiency
and MetS prevalence [35–37].
Barbalho et al. found that 80% of patients in a cardiology unit had vitamin D deficiency
and that all of the patients with hypovitaminosis D had MetS. They also observed signifi-
cantly higher levels of glycemia, glycosylated hemoglobin, total cholesterol, LDLs, triglyc-
erides, and atherogenic indices and an elevated body mass index in patients with vitamin D
deficiency in comparison to those with adequate vitamin D levels [38]. Vimaleswaran et al.,
meanwhile, noted that increased plasma concentrations of 25(OH)D might reduce the risk
of hypertension. Each 25(OH)D-increasing allele of the synthesis score was associated with
a change of −0.10 mm Hg in systolic blood pressure and a change of −0.08 mm Hg in
diastolic blood pressure [39]. However, some authors question or discuss the association
between vitamin D deficiency and components associated with MetS [40–42]. Likewise,
Mehri et al. pointed out that the absence of a long follow-up meant that a causative rela-
tionship could not be definitively established between inadequate vitamin D levels and
MetS [43]. Teixeira et al. considered vitamin D deficiency to be secondary to the metabolic
changes in MetS, although it was associated with IR, which is closely related to the devel-
opment of MetS [44]. Similarly, Chen et al. described that the Mendelian randomization
(MR)-derived odds ratio of genetically determined 25(OH) D for risk of MetS was 0.977,
and therefore, it cannot be concluded that genetically conditioned reduction in vitamin D
levels can increase the risk of metabolic syndrome or any of its components [45]. All of
these authors call for further research to elucidate this relationship.
In summary, the relationship between vitamin D deficiency and the components of
MetS remains a controversial issue because no conclusive scientific evidence is available.
Thus, the main findings of the previously cited studies are summarized in Table 1.
Table 1. Key findings of reviewed studies.
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Table 1. Cont.
Ref. Year MetS and Vit D Objective Methodology Findings
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5. Effect of Vitamin D Supplementation on MetS
Vitamin D supplementation has been reported to exert a beneficial effect in the treat-
ment of MetS-related diseases, such as lipid profile, insulin resistance and hyperglycemia,
obesity, and hypertension [46] (Table 2). This effect could be based on the mechanism of
action of vitamin D on different physiological parameters, including improved arterial
stiffness; decreased renin-angiotensin-aldosterone system activity, parathyroid hormone
levels, inflammatory cytokines; increased activity of lipoprotein lipase; and improved
phospholipid metabolism and mitochondrial oxidation [47].
5.1. Vitamin D Supplementation and Insulin Resistance and Hyperglycemia
In relation to IR, several studies have shown positive effects of vitamin D supplemen-
tation in pre-diabetic patients [48,49]. In their work, Lemieux et al. demonstrated that
supplementation with 5000 IU daily of vitamin D for 6 months increased insulin sensitivity
and pancreatic β-cell activity [48]. Other authors showed the benefits of supplementation
with 50,000 IU/week of vitamin D for 8 weeks in patients with type 2 diabetes, with a
reduction in glycosylated hemoglobin and an increase in sirtuin 1, which appears to be
related to increased insulin secretion by pancreatic β-cells [50]. In their study on dia-
betic patients, Farrokhian et al. also observed that an administration pattern of 50,000 IU
every 2 weeks for 6 months reduces basal glycemia, increasing insulin sensitivity [51].
Furthermore, in this population, co-supplementation with vitamin D (50,000 IU, twice a
week for six months) and omega-3 fatty acids has also been found to produce a significant
decrease in fasting blood glucose levels, increasing insulin sensitivity [52]. However, other
studies seem to show that vitamin D administration has no effect on insulin resistance in
pre-diabetic patients [53]. Lerchbaum et al. further claimed that vitamin D treatment might
have a negative effect on insulin sensitivity in healthy men [54].
5.2. Vitamin D Supplementation and Dyslipidemia
According to the scientific literature, vitamin D supplementation may also exert a
beneficial effect on the lipid profile. In this regard, Gadheri et al. showed a significant
reduction in triglyceride and low-density lipoprotein cholesterol (LDL) levels after sup-
plementation with 50,000 IU of vitamin D every 2 weeks for 3 months [55]. Jamilian et al.,
who used the same doses for 6 months, observed improvements in triglycerides and very-
low-density lipoprotein cholesterol [56]. Other administration patterns have also been
effective in reducing plasma lipid levels, such as those proposed by Riek et al. or Imga et al.,
which led to a decrease in LDL [57,58], or that proposed by Liyanage et al., who suggested
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that parenteral administration of vitamin D leads to an increase in plasma high-density
lipoprotein cholesterol (HDL) levels [59]. The favorable effects of this vitamin on HDL
described above have been corroborated by the meta-analysis developed by Ostadmo-
hammadi et al. [60]. Furthermore, these changes in lipid profile have also been found in
children with type I diabetes [61]. However, Farrokhian et al. found no significant changes
in the lipid profile following vitamin D administration, although they did observe changes
in plasma malonaldehyde levels, which results from lipid peroxidation [51], results that
were later corroborated by Tamadon et al. [62].
5.3. Vitamin D Supplementation and Obesity
With regard to the effects on obesity, according to two meta-analyses recently pub-
lished, it has been shown that vitamin D supplementation could contribute to reduced
body mass index (BMI) and waist circumference, but not weight loss [63]. In this line, a
meta-analysis of 22 observational studies determined that despite an inverse relationship
between the percentage of fat mass and serum vitamin D levels, vitamin D supplementation
was not found to significantly decrease the percentage of fat mass with respect to placebo
groups [64]. In contrast, Lotfi-Dizaji et al. observed a decrease in weight and fat mass in
those subjects with vitamin D deficiency who took 50,000 IU of vitamin D for 12 weeks [65].
However, there are studies showing contrary results, finding no beneficial effect of vitamin
D supplementation at the level of parameters such as BMI, weight, hip circumference, or
fat percentage [66–69]. Similarly, recent studies in individuals aged 6–14 years showed that
vitamin D supplementation did not demonstrate any effect on BMI, waist circumference,
waist-to-hip ratio, and percentage of fat tissue [70–72]. Nevertheless, the combined action
of calcium supplementation together with vitamin D3 appears to increase weight loss and
improve some of the blood metabolic profiles in obese women [66].
5.4. Vitamin D Supplementation and Hypertension
A significant reduction in blood pressure has been observed following the adminis-
tration of vitamin D [73,74], although Golzarand et al. observed that in some cases, this
supplementation can cause hypotension in both healthy and hypertensive subjects [73].
However, further analyses performed on randomized clinical trials that aimed to study the
effect of such supplementation on blood pressure (BP) reported that there is no significant
effect on systolic (SBP) or diastolic (DBP) blood pressure values [75–77]. Similar results
are obtained by studying supplementation in non-adult populations [78]. However, a
recently published clinical trial not included in the previous review indicates that after
6 months of supplemental treatment at the dose of 1000 IU daily could decrease SBP and
DBP figures [70]. Whenever the effect of combined vitamin D and calcium supplementa-
tion on BP is analyzed, the results are very heterogeneous; whereas some authors find no
significant effect on SBP and a reduction of DBP [79], others observed an elevation of SBP
and DBP [73].
5.5. Vitamin D Supplementation Dosage
No consensus has been reached on the optimal treatment of vitamin D deficiency.
Various regimens of daily or monthly doses of cholecalciferol have all obtained suit-
able outcomes. Carbonare et al. found that 80% of patients receiving 1750 IU/day or
50,000 IU/month supplementation for six months reached serum 25(OH)D
levels > 30 ng/mL [80]. Optimal vitamin D levels are clearly beneficial for metabolic
and cardiovascular health in general [15,81]. Various authors have emphasized the need
for supplementation to maintain adequate vitamin D levels and thereby reduce the risk
of MetS and associated diseases [46,82]. Therefore, it appears essential to determine the
vitamin D levels of populations for the development of supplementation interventions and
to implement public health programs on healthy habits that prevent vitamin D deficiency.
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Table 2. Summary of the effects of vitamin D supplementation on metabolic syndrome.
Ref. Year Supplementation Characteristics Findings
Lemieux et al. [48] 2019 Vitamin D3 5000 IU daily, 6 months
In pre-diabetic patients, vitamin D supplementation
for 6 months significantly increased peripheral
insulin sensitivity and β-cell function.
Babarawi et al. [49] 2020
In patients with prediabetes, vitamin D
supplementation at moderate to high doses (≥1000
IU/day) significantly reduced the incidence risk of
T2DM compared with placebo.
Safarpour et al. [50] 2020 50,000 IU/week vitamin D(Zahravi Co® pearls), 8 weeks
Vitamin D supplementation improved T2D by
decreasing HbA1c and increasing SIRT1.
Farrokhian et al. [51] 2017 50,000-IU vitamin D supplementsevery 2 weeks, 6 months
Compared with placebo, vitamin D supplementation
resulted in significant reductions in fasting plasma
glucose, serum insulin, homeostasis model
assessment of insulin resistance, and β cell function.
Talari et al. [52] 2019
50,000 IU vitamin D supplements
every 2 weeks + 2 × 1000 mg/day
n-3 fatty acids from flaxseed oil, 6
months
Vitamin D and n-3 fatty acids’ co-supplementation
led to a significant reduction in fasting plasma
glucose, insulin, insulin resistance and LDL, and a
significant increase in insulin sensitivity and HDL
compared with the placebo.
Wallace et al. [53] 2019 3000 IU (75 µg) vitamin D3 daily,26 weeks
There was no difference between treatment and
placebo group in measures of whole-body, peripheral,
or hepatic IR or in any measure of glycemic control or
β-cell function.
Lerchbaum et al. [54] 2019 20,000 IU of vitamin D3/week, 12weeks
In healthy middle-aged men, vitamin D treatment
had a negative effect on insulin sensitivity.
Ghaderi et al. [55] 2017 50,000 IU vitamin D supplementsevery 2 weeks, 12 weeks
Patients who received vitamin D supplements had
significantly decreased fasting plasma glucose, serum
insulin levels, homeostasis model of
assessment-insulin resistance, serum triglycerides
total, and LDL compared with the placebo.
Jamilian et al. [56] 2017
50,000 IU vitamin D every 2 weeks
+ 1000 mg omega-3 fatty acids
twice a day, 6 weeks
Overall, vitamin D and omega-3 fatty acids
co-supplementation for 6 weeks among gestational
diabetes patients had beneficial effects on fasting
plasma glucose, serum insulin levels, the homeostatic
model of assessment for insulin resistance,
quantitative insulin sensitivity check index, serum
triglycerides, and very-low-density lipoprotein
cholesterol levels.
Imga et al. [57] 2019
100,000 IU/week as a loading dose
for 8 weeks following a
maintenance dose of 3000 IU/day
After the sixth month of supplementation in both
overweight and obese subjects, a significant reduction
was detected in HOMA-IR, low-density lipoprotein
cholesterol, and parathyroid hormone levels.
Riek et al. [58] 2018 Vitamin D3 4000 IU/day for 4months
Assessment of oxidized LDL uptake in monocytes
cultured in the patient’s own serum before vs. after
treatment resulted in >50% reduction in the vitamin
D group with no change in the placebo group. The
reduction in monocyte cholesterol uptake was
reflected in a 19% decrease in total monocyte
cholesterol content.
Liyanage et al. [59] 2017
50,000 IU of vitamin D3
intramuscularly, monthly for 6
months
There was a significant improvement of serum HDL
level with six months of therapy of high-dose vitamin
D in patients with early diabetic nephropathy.
Nutrients 2021, 13, 830 11 of 17
Table 2. Cont.
Ref. Year Supplementation Characteristics Findings
Ostadmohammadi et al.
[60] 2019
This meta-analysis demonstrated the beneficial
effects of vitamin D supplementation on improving
glycemic control, HDL, and C-reactive protein levels
among patients with cardiovascular diseases.
Hafez et al. [61] 2019 VD3 in the form of 4000 IU/dayfor a period of 4 months
After 4 months of vitamin D supplementation, the
mean difference (at 0 and 4 months) in LDL and
HbA1c was statistically significant.
Tamadon et al. [62] 2018
oral vitamin D3 supplements at a
dosage of 50,000 IU every 2 weeks
for 12 weeks
No significant effect of vitamin D supplementation
on lipid profiles and other biomarkers of
inflammation and oxidative stress compared with the
placebo was observed.
Perna [63] 2019
Vitamin D3 supplementation, from
25,000 to 600,000 IU/monthly of
cholecalciferol. Duration of the
treatment: from 1 to 12 months.
Cholecalciferol supplementation decreases the BMI
by −0.32 kg/m2 and the waist circumference by
−1.42 cm but does not statistically affect weight loss
−0.43 kg.
Golzarand et al. [64] 2018
Supplementation from 400 to 7000
IU of daily cholecalciferol.
Duration of the treatment: range
from 3 to 12 months.
Cholecalciferol supplementation increased in
individuals after the intervention. A decrease in body
fat percentage was found (−0.31%, 95% CI: −1.07 to
0.44), although this was not significant.
Lotfi-Dizaji et al. [65] 2019
Weekly bolus dose of 50,000 UI od
vitamin D. Duration of the
treatment: 12 weeks.
An increase in serum 25(OH)D levels was found after
vitamin D administration. The analysis showed a
significant decrease in weight and body fat
percentage after comparison between groups.
Subih et al. [66] 2020
Supplementation consisted of
vitamin D3, with doses of 50,000
IU weekly, or vitamin D3
combined with calcium, with
doses of 50,000 IU weekly of
vitamin D and 1,200 mg/dL daily
of calcium. Duration of the
treatment: 3 months.
Compared to the control group, those women
supplemented with vitamin D did not show
significant changes related to weight loss or
improvement of obesity biomarkers. However, after
co-supplementation of calcium and vitamin D, a
decrease in weight was reported, as well as an
improvement in some of the blood metabolic profiles.
Duan et al. [67] 2018
Daily doses of vitamin D
supplementation from 100 to 8571
UI. Duration of the treatment:
range from 1.5 to 36 months.
Comparisons with the placebo or control group
determined that neither BMI nor waist circumference
decreased significantly after vitamin D
administration.
Gallagher et al. [68] 2013
Daily doses of vitamin D ranged
from 400 to 4800 IU. Duration of
the treatment: 12 months.
Although an inverse relationship was found between
serum vitamin D levels and fat mass, between-group
analyses found no significant reductions in BMI or fat
mass after supplementation.
Chandler et al. [69] 2015
When compared with placebo, vitamin D
supplementation had no significant effect on BMI,
weight, or fat mass. Likewise, no significant
reduction in BMI, weight, or fat mass was observed
in participants who received vitamin D plus calcium
compared with those who received calcium control.
Rajakumar et al. [70] 2020
Daily vitamin D oral doses
containing 600, 1000, and 2000 UI.
Duration of the treatment: 6
months.
Vitamin D supplementation showed no effect on BMI,
waist circumference, waist-to-hip ratio, and
percentage of fat tissue in children. In contrast, a
significant decrease in SBP and DBP levels was
observed after daily administration of 1000 IU.
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Brzeziński et al. [71] 2020
Daily supplementation of 1200 UI
of vitamin D. Duration of the
treatment: 26 weeks.
There showed no significant decrease in either BMI
or weight of obese children in comparison with the
placebo group.
Makariou et al. [72] 2020
The vitamin D administration
regimen was 2000 IU daily for a
duration of 3 months.
The results did not show a relationship between
vitamin D supplementation and BMI, blood
pressure, lipids, glucose, and insulin levels, among
others.
Golzarand et al. [73] 2016
The dose of vitamin D
administration ranged from 200 to
12,000 IU per day. The mean
duration of treatment was 5.6 ± 4.0
months.
The results showed that the daily administration of
vitamin D supplementation in doses higher than 800
IU in subjects older than 50 years significantly
reduced both SBP and DBP (p < 0.001). Moreover,
hypotensive effects were observed in both the group
of healthy subjects and the group of hypertensive
subjects.
Shu & Huang [74] 2018
The daily dose of vitamin D
administered was from 2800 UI to
more than 5000 UI. Duration of the
treatment: from 8 to 20 weeks.
Results show a significant effect of vitamin D
supplementation on peripheral DBP in vitamin
D-deficient participants, but not the same with
peripheral SBP. Subgroup analysis showed a
significant decrease in peripheral SBP and DBP in
Asia, 8 weeks of intervention, and more than 5000 IU
of daily vitamin D supplementation subgroups.
Wu et al. [75] 2010
The vitamin D dose administered
varied in a range between 200 IU
and 400 UI per day. Duration of the
treatment: from 5 to 15 weeks.
The analysis concluded that vitamin D
supplementation reduced SBP by 2.44 mmHg, but
no effect on DBP was observed compared to the
placebo groups.
Hussin et al. [76] 2017
The daily vitamin D administration
regimen varied between 1000 UI
and 5000 UI. Treatment duration
ranged from 4 to 52 weeks.
The effects of vitamin D supplementation showed
no improvement in endothelial function. Specifically,
no significant changes in blood pressure,
post-occlusive vasodilation of the brachial artery,
among others, were observed.
Swart et al. [77] 2018
Vitamin D supplementation varies
between 200 IU and 7000 IU daily.
The duration of treatment ranged
from 8 weeks to 1 year.
All the studies analyzed found a significant increase
in serum vitamin D levels. However, vitamin D
supplementation had no effect on SBP and DBP.
Abboud et al. [78] 2020
Vitamin D administration regimens
were in a daily range between 400
IU and 43,000 IU, with a duration
between 12 and 24 weeks.
The results showed that vitamin D supplementation




Vitamin D was administered daily
between 200 IU and 7142 IU.
Calcium dosage ranged from 500 to
1200 mg daily. Treatment duration
ranged from 6 weeks to 7 years.
Vitamin D and calcium co-supplementation did not
show a reduction in SBP compared to the control
group, although a significant decrease in DBP was
found.
Carbonare et al. [80] 2018 Vitamin D3
Two regimens were equivalent; most of the patients
reached the normal range of vitamin D after six
months of treatment with increased calcium levels
and decreased bone turnover. Waist circumference
also decreased. The relationship between serum
25(OH)vitamin D3 concentration and waist
circumference supports vitamin D having a
protective role in the current setting since waist size
is directly associated with the risk of cardiovascular
and metabolic diseases.
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Al-Daghri et al. [82] 2019 Vitamin D3vitamin D-fortifiedmilk
There was an increase in 25(OH)D levels in all groups.
It is also revealed a clinically significant decrease in
triglycerides, glucose, and systolic blood pressure, as
well as a clinically significant increase in HDL over
time, all in favor of the Vit D group. MetS incidence
did decrease in the Vit. D group only. Consequently,
oral vitamin D supplementation is superior to
vitamin D-fortified milk in improving vitamin D
status. Reduction in the incidence of MetS in the
Arab adolescent population secondary to vitamin D
correction may be dose-dependent.
HbA1c: hemoglobin A1c; BMI: body mass index; DBP: diastolic blood pressure; SBP: systolic blood pressure; HDL: high-density lipoprotein
cholesterol; LDL: low-density lipoprotein cholesterol; T2DM: type 2 diabetes mellitus; HOMA-IR: Homeostatic Model Assessment for
Insulin Resistance.
6. Conclusions
According to the different studies analyzed in this review, vitamin D deficiency ap-
pears to be associated with the different components that define MetS. Similarly, vitamin D
supplementation may be an appropriate strategy in the treatment of MetS. However, it
is not possible to draw a clear conclusion on this association as the published data are
contradictory and it is not clear whether vitamin D deficiency is a cause or effect of the
metabolic syndrome or any of its components. Therefore, further studies are needed to
determine the real role of vitamin D deficiency in the development of MetS.
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